Medicare Enrolled
Dr. Lawrence Bistrong, M.D.
Pulmonary Disease · Roseville, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Bistrong from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Bistrong?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Bistrong
Dr. Lawrence Bistrong is a pulmonary disease specialist in Roseville, CA, with 18 years of NPI registration. Based on federal Medicare data, Dr. Bistrong performed 2,280 Medicare services across 2,073 unique beneficiaries.
Between the years covered by Open Payments, Dr. Bistrong received a total of $4,781 from 47 pharmaceutical and/or device companies across 224 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Bistrong is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 17% volume in CA
$4,781 industry payments
Medicare Practice Summary
Medicare Utilization ↗2,280
Medicare services
Top 17% in CA for pulmonary disease
2,073
Unique beneficiaries
$59
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~127 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
466 | $46 | $115 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
456 | $48 | $174 |
| Expiratory airflow and volume test A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume. |
300 | $23 | $100 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
234 | $33 | $175 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
196 | $66 | $225 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
107 | $175 | $665 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
93 | $98 | $300 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
86 | $71 | $200 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
82 | $98 | $300 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
52 | $106 | $397 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
48 | $138 | $465 |
| Exercise-induced lung stress test A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising. |
24 | $26 | $108 |
| Breathing device use evaluation An assessment of how a patient uses a breathing device. The provider reviews the patient's technique and device handling. |
24 | $15 | $44 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
23 | $85 | $300 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
18 | $129 | $405 |
| Additional 30 minutes of critical care This code represents an additional 30 minutes of critical care services provided beyond the initial critical care time period. |
15 | $88 | $330 |
| Smoking cessation counseling, 4-10 minutes A brief counseling session focused on helping patients quit smoking and tobacco use. The provider spends 4 to 10 minutes discussing strategies and support for cessation. |
15 | $13 | $40 |
| Lung function test at high altitude A test to measure how well the lungs are working while at high altitude. |
14 | $40 | $170 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
14 | $147 | $585 |
| High altitude lung function and oxygen needs test A test to measure lung function at high altitude and evaluate oxygen requirements during rest and exercise. |
13 | $59 | $235 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$4,781
Total received (2018-2024)
Avg $683/year across 7 years
Top 28% in CA for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
47
Companies
224
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,781 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$881
2023
$1,468
2022
$489
2021
$358
2020
$283
2019
$741
2018
$560
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ViiV Healthcare Company
$205
GlaxoSmithKline, LLC.
$104
ABBVIE INC.
$100
United Therapeutics Corporation
$93
Insmed, Inc.
$54
Boehringer Ingelheim Pharmaceuticals, Inc.
$45
Medtronic, Inc.
$39
Inari Medical, Inc.
$37
AstraZeneca Pharmaceuticals LP
$33
Regeneron Healthcare Solutions, Inc.
$29
JAZZ PHARMACEUTICALS INC.
$28
Astellas Pharma US Inc
$26
PFIZER INC.
$25
La Jolla Pharmaceutical Company
$24
Pulmonx Corporation
$24
Grifols USA, LLC
$15
Top 3 companies account for 46.4% of 2024 payments
All-time payments by company (2018-2024) ›
Medtronic, Inc.
$748
GlaxoSmithKline, LLC.
$716
ViiV Healthcare Company
$445
Boehringer Ingelheim Pharmaceuticals, Inc.
$395
AstraZeneca Pharmaceuticals LP
$233
Intuitive Surgical, Inc.
$153
Allergan Inc.
$141
Grifols USA, LLC
$140
ABBVIE INC.
$137
United Therapeutics Corporation
$116
Gilead Sciences, Inc.
$94
AbbVie Inc.
$89
Merck Sharp & Dohme LLC
$89
Mylan Specialty L.P.
$86
Insmed, Inc.
$81
Electromed, Inc.
$81
Takeda Pharmaceuticals U.S.A., Inc.
$77
Genentech USA, Inc.
$59
Regeneron Healthcare Solutions, Inc.
$58
Amgen Inc.
$57
Baxter Healthcare
$56
ZOLL Circulation Inc
$50
Kerecis Limited
$48
Sunovion Pharmaceuticals Inc.
$47
Merck Sharp & Dohme Corporation
$45
PFIZER INC.
$43
TETRAPHASE PHARMACEUTICALS, INC.
$40
Inari Medical, Inc.
$37
Philips Electronics North America Corporation
$35
Allergan, Inc.
$33
Bayer HealthCare Pharmaceuticals Inc.
$30
JAZZ PHARMACEUTICALS INC.
$28
Astellas Pharma US Inc
$26
Mallinckrodt Hospital Products Inc.
$25
La Jolla Pharmaceutical Company
$24
Pulmonx Corporation
$24
Shionogi Inc
$23
Alexion Pharmaceuticals, Inc.
$22
Shire North American Group Inc
$21
Horizon Therapeutics plc
$21
PORTOLA PHARMACEUTICALS, LLC
$18
Fisher & Paykel Healthcare Inc
$18
Teva Pharmaceuticals USA, Inc.
$17
Janssen Biotech, Inc.
$15
EMD Serono, Inc.
$14
Paratek Pharmaceuticals, Inc.
$13
Advanced Respiratory, Inc
$13
Top 3 companies account for 39.9% of all-time payments
Associated products mentioned in payments ›
ACTHAR · ACTIMMUNE · ANDEXXA · ANORO · ANORO ELLIPTA · APRETUDE · AVYCAZ · Adempas · Arikayce · BEVESPI AEROSPHERE · BREO · BREZTRI · BREZTRI AEROSPHERE · BROVANA · CABENUVA · CHANTIX · CHARTIS CATHETER · Cresemba · DIFICID · DOVATO · DUPIXENT · DUPIXENT DUPILUMAB INJECTION · Da Vinci Surgical System · ELIQUIS · Esbriet · FASENRA · FISHER & PAYKEL HEALTHCARE · FLOWTRIEVER CATHETER · Fetroja · GIAPREZA · GLASSIA · Hillrom - Life 2000 Ventilation System · Hillrom - Vest System Model 105 Home Care · ILLUMISITE · ISENTRESS · Kerecis Omega3 SurgiClose · LONHALA MAGNAIR · NUCALA · NUZYRA · OFEV · ORENITRAM · PIFELTRO · Personal Care Undiv · Prolastin-C Liquid · QVAR · RUKOBIA · S · SEROSTIM · SMARTVEST · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SYMBICORT · SYMTUZA · TEFLARO · TEZSPIRE · TRELEGY ELLIPTA · TYVASO · Tavneos · Temperature Management System · The Vest System Model 105 Home Care · Trilogy 100 · ULTOMIRIS · Utibron · XYWAV · Xerava · YUPELRI · Yupelri · ZERBAXA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Pulmonary diseases within 10 mi
40
Per 100K population
9.7
County median income
$114,678
Nearest hospital
SUTTER ROSEVILLE MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Bistrong is a mixed practice specialist, with above-average Medicare volume (top 17% in CA), with low-engagement industry engagement, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Bistrong experienced with lung volume test using sensors?
Based on Medicare claims data, Dr. Bistrong performed 466 lung volume test using sensors services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Bistrong receive payments from pharmaceutical companies?
Yes. Dr. Bistrong received a total of $4,781 from 47 companies across 224 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Bistrong's costs compare to other pulmonary diseases in Roseville?
Dr. Bistrong's average Medicare payment per service is $59. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Bistrong) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Roseville
Browse pulmonary diseases in Roseville ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in CA
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in CA
Which CA pulmonary diseases receive the most from drug and device companies.
By company
Medtronic, Inc. Payments to Doctors
See all physicians who received payments from Medtronic, Inc.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
ViiV Healthcare Company Payments to Doctors
See all physicians who received payments from ViiV Healthcare Company.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology